Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: The experience in four centers

Biology of Blood and Marrow Transplantation

Volumn 7, Issue 1, 2001, Pages 39-45

  Storb, Rainer ^a   Blume, Karl G ^a   O'Donnell, Margaret R ^a   Chauncey, Tom ^a   Forman, Stephen J ^a   Deeg, H Joachim ^a   Hu, Wendy W ^a   Appelbaum, Frederick R ^a   Doney, Kris ^a   Flowers, Mary E D ^a   Sanders, Jean ^a   Leisenring, Wendy ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Allogeneic marrow grafts; Aplastic anemia; Cyclophosphamide and antithymocyte globulin conditioning

Indexed keywords

ANDROGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HLA ANTIGEN; MEPREDNISONE; METHOTREXATE; PREDNISONE; STEROID; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; RATING SCALE; SIDE EFFECT; SURVIVAL RATE; TREATMENT FAILURE;

EID: 0035097170     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2001.v7.pm11215697     Document Type: Article

References (50)

1. Allogeneic marrow transplants in cyclophosphamide treated mice
2. Allogeneic canine bone marrow transplantation following cyclophosphamide
3. Cyclophosphamide regimens in rhesus monkeys with and without marrow infusion
4. Marrow transplantation in man following cyclophosphamide
5. Aplastic anaemia treated by marrow transplantation
6. Allogeneic marrow grafting for treatment of aplastic anemia
7. Aplastic anemia treated by allogeneic bone marrow transplantation: A report on 49 new cases from Seattle
8. Bone-marrow transplantation in severe aplastic anaemia
9. Bone marrow transplantation from histocompatible, allogeneic donors for aplastic anemia: A report from the ACS/NIH bone marrow transplant registry
10. The effect of prior transfusion on marrow grafts between histocompatible canine siblings
11. The influence of transfusions from unrelated donors upon marrow grafts between histocompatible canine siblings
12. Effect of prior blood transfusions on marrow grafts: Abrogation of sensitization by procarbazine and antithymocyte serum
13. Effect of six weekly transfusions on canine marrow grafts: Tests for sensitization and abrogation of sensitization by procarbazine and antithymocyte serum
14. Second marrow transplants in patients with aplastic anemia rejecting the first graft: Use of a conditioning regimen including cyclophosphamide and antithymocyte globulin
15. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia
16. Marrow transplantation for Fanconi anaemia: Conditioning with reduced doses of cyclophosphamide without radiation
17. Marrow transplantation for severe aplastic anemia: Methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease
18. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease
19. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors
20. Methods for assessment of graft-versus-host disease
21. Chronic graft-versus-host disease and other late complications of bone marrow transplantation
22. Documentation of engraftment and characterization of chimerism following hematopoietic cell transplantation
23. Nonparametric estimation from incomplete observations
24. A qualifier Q for the survival function to describe the prevalence of a transient condition
25. Treatment of graft failure with anti-CD3 antibody BC3, glucocorticoids and infusion of donor hematopoietic cells
26. Increased incidence of malignant tumors in dogs after total body irradiation and marrow transplantation
27. Cumulative incidence of secondary solid malignant tumors in aplastic anemia patients given marrow grafts after conditioning with chemotherapy alone
28. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: A joint Seattle and Paris analysis of results in 700 patients
29. Ovarian function following marrow transplantation for aplastic anemia or leukemia
30. Growth and development after bone marrow transplantation
31. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation
32. Rejection of marrow from DLA-identical canine littermates given transfusions before grafting: Antigens involved are expressed on leukocytes and skin epithelial cells but not on platelets and red blood cells
33. Prevention of transfusion-induced sensitization to minor histocompatibility antigens on DLA-identical canine marrow grafts by gamma irradiation of marrow donor blood
34. Gamma-irradiation of pretransplant blood transfusions from unrelated donors prevents sensitization to minor histocompatibility antigens on dog leukocyte antigen-identical canine marrow grafts
35. Bone marrow transplantation in pediatric patients with severe aplastic anemia: Cyclophosphamide and anti-thymocyte globulin conditioning followed by recombinant human granulocyte-macrophage colony stimulating factor
36. Cyclophosphamide/antithymocyte globulin conditioning of patients with severe aplastic anemia for marrow transplantation from HLA-matched siblings: Preliminary results
37. Conditioning with cyclophosphamide/antithymocyte globulin for allogeneic bone marrow transplantation from HLA-matched siblings in children with severe aplastic anemia
38. Bone marrow transplant for severe aplastic anemia: Has outcome improved?
39. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation
40. Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including anti-T-cell antibodies
41. Antithymocyte serum and methotrexate for control of graft-versus-host disease in dogs
42. Modification of the graft-versus-host syndrome by anti-lymphocyte serum treatment of the host
43. Treatment and pretreatment of graft-versus-host reaction by antilymphocyte serum
44. Suppression of acute secondary disease in the mouse with antilymphocyte serum
45. Bone marrow transplantation in rhesus monkeys following irradiation: Modification of acute graft-versus-host disease with antilymphocyte serum
46. The effect of pretreatment of allogeneic bone marrow graft recipients with antilymphocytic serum on the acute graft-versus-host reaction in monkeys
47. Suppression of immune competent cell reactivity by antilymphocyte serum
48. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation
49. Secondary malignancies after marrow transplantation for leukemia or aplastic anemia